ClinicalTrials.gov
skipnavHome|Search|Browse|Resources|Help|What's New|About

Safety and Efficacy Study of RTS,S AS02A/AS01B Vaccine to Prevent Malaria

This study is currently recruiting patients.

Sponsored by: Walter Reed Army Institute of Research (WRAIR)
GlaxoSmithKline
Information provided by: Walter Reed Army Institute of Research (WRAIR)

Purpose

This is a double blinded study where 2 test vaccines will be evaluated to see if they protect persons who have never had malaria against malaria infection when bitten by mosquitoes.

Condition Treatment or Intervention Phase
Malaria
 Vaccine: RTS,S with AS02A/AS01B adjuvant
Phase I
Phase II

MedlinePlus related topics:  Malaria

Study Type: Interventional
Study Design: Prevention, Randomized, Double-Blind, Active Control, Single Group Assignment, Safety/Efficacy Study

Further Study Details: 

Expected Total Enrollment:  104

Study start: December 2003

Eligibility

Ages Eligible for Study:  18 Years   -   45 Years,  Genders Eligible for Study:  Both

Accepts Healthy Volunteers

Criteria


Location and Contact Information


Maryland
      Walter Reed Army Institute of Research, Silver Spring,  Maryland,  20910,  United States; Recruiting
Oman Q Salazar  866-856-3259    clinical2@na.amedd.army.mil 
Felicia L Breedy  866-856-3259    clinical2@na.amedd.army.mil 
Kent E Kester, MD,  Principal Investigator

More Information

Clinical Trials Center website

Study ID Numbers:  1032; 257049/027; Malaria-027
Record last reviewed:  March 2004
Record first received:  December 31, 2003
ClinicalTrials.gov Identifier:  NCT00075049
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2004-11-09
line
U.S. National Library of Medicine, Contact NLM Customer Service
National Institutes of Health, Department of Health & Human Services
Copyright, Privacy, Accessibility, Freedom of Information Act